Vikram Purohit
Stock Analyst at Morgan Stanley
(0.73)
# 3,405
Out of 4,667 analysts
185
Total ratings
20.83%
Success rate
-21.35%
Average return
Main Sectors:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: Equal-Weight | $64 → $69 | $71.05 | -2.89% | 23 | Oct 30, 2024 | |
| ZBIO Zenas BioPharma | Initiates: Overweight | $40 | $12.45 | +221.29% | 1 | Oct 8, 2024 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $7.86 | +14.50% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $20.45 | +51.59% | 2 | Sep 11, 2024 | |
| SLRN Acelyrin | Maintains: Equal-Weight | $13 → $6 | $4.43 | +35.44% | 7 | Aug 19, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $59 → $64 | $45.76 | +39.86% | 6 | Aug 7, 2024 | |
| ABSI Absci | Initiates: Overweight | $7 | $2.68 | +161.19% | 1 | Jul 3, 2024 | |
| ASND Ascendis Pharma | Maintains: Equal-Weight | $116 → $140 | $124.38 | +12.56% | 18 | May 16, 2024 | |
| AXSM Axsome Therapeutics | Upgrades: Overweight | $90 → $115 | $94.60 | +21.56% | 18 | Apr 29, 2024 | |
| EXAI Exscientia | Maintains: Equal-Weight | $7 | $4.84 | +44.63% | 16 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $16 | $8.86 | +80.59% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $4.66 | +543.78% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $22 | $4.91 | +348.07% | 6 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $10.18 | -1.77% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $1.72 | +248.84% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $9.63 | +336.14% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $11 | $6.04 | +82.12% | 1 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $23 | $2.72 | +727.21% | 4 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $44.05 | -6.92% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $23.36 | +71.23% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $1.65 | +687.88% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $19.17 | +98.23% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $9.55 | +109.42% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $9.97 | +0.30% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $18 → $7 | $18.46 | -62.08% | 8 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $4.12 | +433.98% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $4 | $0.51 | +687.40% | 2 | Aug 5, 2020 |
Incyte
Oct 30, 2024
Maintains: Equal-Weight
Price Target: $64 → $69
Current: $71.05
Upside: -2.89%
Zenas BioPharma
Oct 8, 2024
Initiates: Overweight
Price Target: $40
Current: $12.45
Upside: +221.29%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $7.86
Upside: +14.50%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $20.45
Upside: +51.59%
Acelyrin
Aug 19, 2024
Maintains: Equal-Weight
Price Target: $13 → $6
Current: $4.43
Upside: +35.44%
Halozyme Therapeutics
Aug 7, 2024
Maintains: Overweight
Price Target: $59 → $64
Current: $45.76
Upside: +39.86%
Absci
Jul 3, 2024
Initiates: Overweight
Price Target: $7
Current: $2.68
Upside: +161.19%
Ascendis Pharma
May 16, 2024
Maintains: Equal-Weight
Price Target: $116 → $140
Current: $124.38
Upside: +12.56%
Axsome Therapeutics
Apr 29, 2024
Upgrades: Overweight
Price Target: $90 → $115
Current: $94.60
Upside: +21.56%
Exscientia
Apr 22, 2024
Maintains: Equal-Weight
Price Target: $7
Current: $4.84
Upside: +44.63%
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $8.86
Upside: +80.59%
Apr 1, 2024
Initiates: Overweight
Price Target: $30
Current: $4.66
Upside: +543.78%
Feb 28, 2024
Maintains: Equal-Weight
Price Target: $20 → $22
Current: $4.91
Upside: +348.07%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $10.18
Upside: -1.77%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $1.72
Upside: +248.84%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $9.63
Upside: +336.14%
Jul 13, 2023
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $6.04
Upside: +82.12%
Jun 5, 2023
Maintains: Equal-Weight
Price Target: $20 → $23
Current: $2.72
Upside: +727.21%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $44.05
Upside: -6.92%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $23.36
Upside: +71.23%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $1.65
Upside: +687.88%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $19.17
Upside: +98.23%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $9.55
Upside: +109.42%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $9.97
Upside: +0.30%
Dec 10, 2021
Downgrades: Underweight
Price Target: $18 → $7
Current: $18.46
Upside: -62.08%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $4.12
Upside: +433.98%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $8 → $4
Current: $0.51
Upside: +687.40%